Please assess the completion status of the following clinical trial:

Trial Title: Pilot Study of Hepatitis C Virus Entry Inhibitor (ITX 5061) in Liver Transplant Recipients

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Age ≥ 18 years old, ≤ 65 years old~* Plasma HCV RNA positive at time of listing for liver transplantation~* Accepted for liver transplantation for any of:~* End-stage liver disease due to HCV infection~* End-stage liver disease due to HCV infection and alcohol related liver disease (ALD)~* HCC due to HCV~Exclusion Criteria:~* Refusal or inability to give informed consent~* Viral co-infection with either hepatitis B virus (HBV) or human immunodeficiency virus (HIV)~* Pregnancy or breastfeeding~* Women, of child-bearing potential, who are not willing to practice effective contraception~* Men, sexually active with women of child-bearing potential, who are not willing to practice effective contraception~* Any situation that in the Investigator's opinion may interfere with optimal study participation~* Participation in any clinical study of an investigational agent within 30 days of recruitment~* Transplantation with a donor organ from a HCV positive individual

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 65 Years
- Healthy Volunteers: f

Study Arms:
- Standard liver transplant care (Type: NO_INTERVENTION): Liver Transplantation as per Standard of Care
- ITX 5061 (Type: EXPERIMENTAL): Liver Transplantation as per Standard of Care + ITX5061

Based on this trial design, predict the completion outcome and termination type (if applicable).